A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Flecainide Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm
Latest Information Update: 01 Nov 2023
At a glance
- Drugs Flecainide (Primary)
- Indications Paroxysmal atrial fibrillation
- Focus Registrational; Therapeutic Use
- Acronyms RESTORE-1
- Sponsors InCarda Therapeutics
- 07 Jun 2023 Status changed from recruiting to discontinued.
- 04 Jun 2023 This trial has been Discontinued in Czechia, according to European Clinical Trials Database record.
- 02 Dec 2022 Planned End Date changed from 30 Dec 2023 to 30 Apr 2024.